SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| van Grunsven Jasper | EVP, CP and NPPO | 2026-09-08 | Grant/award | 8682 | $0 |
| Ambrose Kristen | SVP & Chief Accounting Officer | 2026-08-28 | Grant/award | 5000 | $0 |
| SACHS BRUCE I | Director | 2026-08-27 | Gift | 6000 | $0 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 2026-07-21 | Grant/award | 8251 | $0 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 2026-07-21 | Grant/award | 8251 | $0 |
| McKechnie Duncan | EVP, Chief Commercial Officer | 2026-07-02 | Open-market sell 10b5-1 | 1541 | $800K |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 2026-07-02 | Open-market sell 10b5-1 | 1500 | $787K |
| Liu Joy | EVP and Chief Legal Officer | 2026-07-01 | Open-market sell 10b5-1 | 828 | $416K |
| Bozic Carmen | EVP and CMO | 2026-06-26 | Open-market sell 10b5-1 | 596 | $288K |
| Bozic Carmen | EVP and CMO | 2026-06-18 | Open-market sell 10b5-1 | 1020 | $471K |
| Bozic Carmen | EVP and CMO | 2026-06-15 | Open-market sell 10b5-1 | 4062 | $1.8M |
| Bozic Carmen | EVP and CMO | 2026-06-05 | Open-market sell 10b5-1 | 1745 | $785K |
| Liu Joy | EVP and Chief Legal Officer | 2026-06-01 | Open-market sell 10b5-1 | 828 | $364K |
| Bozic Carmen | EVP and CMO | 2026-05-29 | Open-market sell 10b5-1 | 1974 | $888K |
| Bozic Carmen | EVP and CMO | 2026-05-15 | Open-market sell 10b5-1 | 1354 | $614K |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 2026-05-15 | Open-market sell 10b5-1 | 33 | $15K |
| Bozic Carmen | EVP and CMO | 2026-05-12 | Open-market sell 10b5-1 | 6988 | $3.1M |
| Bhatia Sangeeta N. | Director | 2026-05-04 | Open-market sell 10b5-1 | 318 | $135K |
| Bhatia Sangeeta N. | Director | 2026-05-01 | Grant/award 10b5-1 | 943 | $0 |
| Garber Alan M | Director | 2026-05-01 | Grant/award | 472 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Vertex's risk profile worsened materially this year, driven by a broad expansion of regulatory, operational, and legal exposures that outweigh two eased commercialization risks. New disclosures of active government investigations and whistleblower claims, substantially expanded regulatory scrutiny across global markets and new therapeutic areas, and CASGEVY's structurally higher manufacturing cost burden represent concrete, incremental risk — not boilerplate. The two eased items (market acceptance and reimbursement uncertainty for cell/gene therapies) reflect improved commercial conditions but are insufficient to offset the breadth of new downside disclosures.
5 company-specific · 3 eased/removed · 2 common-mode
New disclosure of significantly higher manufacturing costs as percentage of revenue compared to CF medicines, indicating operational and margin pressure on CASGEVY commercialization.
We may not be able to increase or maintain CASGEVY product revenues. The future commercial success of CASGEVY depends on physicians, patients, or payors accepting it as medically useful…
New explicit disclosure of FDA regulatory actions (trial pauses, approval restrictions, withdrawals) and concrete examples of failed programs (VX-264, suzetrigine label setback) escalate regulatory risk.
Risks Related to Product Development The data from our product development activities may not support advancement or regulatory approval of our product candidates, or label expansions for our…
New disclosure of government price reporting/calculation risk and potential restatement liability; expanded scope of regulatory scrutiny and enforcement exposure.
Commercialization of our products requires that we operate in compliance with applicable health care laws, including laws regulating promotional activities, prohibiting fraud and abuse and requiring…
New disclosure of government/regulatory investigations and whistleblower claims against the company; escalation from general product liability risk to active investigations requiring significant resources.
Our business has a substantial risk of product liability claims and other litigation liability. The testing, manufacturing, marketing and use of our products and product candidates involve…
Revised disclosure adds specific third-party types (CROs, CMOs, logistics), expansion into new markets, heightened risks from limited supplier alternatives, and regulatory/reputational harm exposure.
Reliance on third-party relationships could adversely affect our business. Our business depends on relationships with third parties, including activities critical to research, development…
Removal of detailed Medicaid rebate and 340B program compliance risk. Company explicitly eliminated disclosure of material regulatory exposure affecting pricing, rebates, and revenue.
If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional…
Removal of material market acceptance risk for cell/gene therapies suggests improved physician, patient, and payer acceptance—a substantive easing of commercialization risk for CASGEVY and pipeline.
Cell and genetic therapies face increased scrutiny from the public and medical communities and commercial success will depend, in part, upon the acceptance of those communities. There is some degree…
Removal of reimbursement uncertainty risk for cell/genetic therapies suggests improved clarity or reduced concern about coverage barriers to commercialization.
Insurance coverage and reimbursement of cell and genetic therapies is uncertain. There is uncertainty related to the insurance coverage and reimbursement of cell or genetic therapies, including those…
Substantially expanded regulatory risk disclosure. Added new specific risks: global expansion, new therapeutic areas, healthcare reform uncertainty, manufacturing/data/sustainability requirements, trade sanctions, FDA shutdown impact.
Regulatory, Intellectual Property and Other Legal Risks The extensive regulatory framework governing the health care industry could adversely affect our ability to obtain approval and market our…
New disclosure of AI-related cybersecurity and operational risks, including adversarial AI techniques, AI system flaws, and regulatory compliance challenges. Escalates threat landscape beyond traditional cyber-attacks.
A breakdown or breach of our information technology systems, or unauthorized access to confidential information could adversely affect our business. We maintain and rely extensively on information…
Jonathan Poole was appointed as Executive Vice President and Chief Financial Officer effective January 1, 2027. While the disclosure also mentions Charles F. Wagner, Jr. ceasing to serve as CFO, the principal action disclosed is Poole's appointment to a C-suite financial role at a major pharmaceutical company. The filing details his compensation arrangements ($750,000 base salary, 90% target bonus) and change-of-control protections, which are typical components of executive appointment disclosures under Item 5.02(a) and (e).
View raw filing on EDGAR →This is a clear earnings release disclosing Vertex's consolidated financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $3.33 billion (12% increase YoY), net income, and updated full-year 2026 revenue guidance raised to $13.1–$13.2 billion. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →Vertex Pharmaceuticals entered into a definitive merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing a $10 billion total transaction ($8.8 billion net of cash). The acquisition is expected to be transformative, adding endocrinology assets including PALSONIFY and atumelnant to Vertex's pipeline, with $5 billion+ peak sales opportunity and accretion to non-GAAP operating income by 2029.
View raw filing on EDGAR →